159 related articles for article (PubMed ID: 31910388)
1. Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis.
Spiegel DY; Boyer MJ; Hong JC; Williams CD; Kelley MJ; Salama JK; Palta M
J Natl Compr Canc Netw; 2020 Jan; 18(1):52-58. PubMed ID: 31910388
[TBL] [Abstract][Full Text] [Related]
2. Long-term Clinical Outcomes of Nonoperative Management With Chemoradiotherapy for Locally Advanced Rectal Cancer in the Veterans Health Administration.
Spiegel DY; Boyer MJ; Hong JC; Williams CD; Kelley MJ; Moore H; Salama JK; Palta M
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):565-573. PubMed ID: 30359718
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemotherapy Use in Patients With Locally Advanced Rectal Cancer: A Single-Institution Experience.
Li F; Nielsen G; Baran A; Hu J; Wallace D; Preslar M; Fleming F; Temple L; Dunne RF; Noel M; Hezel AF; Tejani MA
Clin Colorectal Cancer; 2020 Sep; 19(3):e124-e128. PubMed ID: 32409226
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Ye W; Shi L; Qian L; Sun Y; Sun X
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
[TBL] [Abstract][Full Text] [Related]
5. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Management of Pathologic Node-Positive Disease After Definitive Surgery for Clinical T1-2 N0 Rectal Cancer.
Polamraju P; Haque W; Verma V; Wiederhold L; Hatch S; Butler EB; Teh BS
Clin Colorectal Cancer; 2018 Sep; 17(3):e519-e530. PubMed ID: 29753642
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis.
Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
Oncologist; 2019 Jun; 24(6):803-811. PubMed ID: 29674444
[TBL] [Abstract][Full Text] [Related]
8. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
Lin Y; Lin H; Xu Z; Zhou S; Chi P
J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
[No Abstract] [Full Text] [Related]
9. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
[TBL] [Abstract][Full Text] [Related]
10. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
11. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
12. Intensified Total Neoadjuvant Therapy
DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
[TBL] [Abstract][Full Text] [Related]
14. Can we eliminate neoadjuvant chemoradiotherapy in favor of neoadjuvant multiagent chemotherapy for select stage II/III rectal adenocarcinomas: Analysis of the National Cancer Data base.
Cassidy RJ; Liu Y; Patel K; Zhong J; Steuer CE; Kooby DA; Russell MC; Gillespie TW; Landry JC
Cancer; 2017 Mar; 123(5):783-793. PubMed ID: 27780316
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy after neoadjuvant chemoradiation and proctectomy improves survival irrespective of pathologic response in rectal adenocarcinoma: a population-based cohort study.
Naffouje SA; Liu YJ; Kamarajah SK; Salti GI; Dahdaleh F
Int J Colorectal Dis; 2022 Oct; 37(10):2137-2148. PubMed ID: 36048196
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
19. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
Seddik Y; Brahmi SA; Afqir S
Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
[TBL] [Abstract][Full Text] [Related]
20. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
